Abstract 3969
Background
Overall colorectal cancer (CRC) incidence and mortality are declining due to cancer screening in older patients population, however, the incidence of CRC is increasing in younger adults (<50 years) among several countries, mostly in the United States and Europe. This study aimed to evaluateclinicopathological characteristics of adolescent and young adult (AYA) onset sporadic CRC and outcome in Thai patients.
Methods
Medical record of patients who were diagnosed adenocarcinoma of colorectal cancer at Siriraj Hospital between 2007 and 2018 were retrospectively reviewed. The patients were classified into 2 groups: AYA-onset CRC (age 15-39 years) and adult-onset CRC (age >50 years). Associations between sporadic microsatellite stable (MSS) AYA- /adult-onset CRC and clinicaopathological features and outcome were evaluated.
Results
A total 202 patients were diagnosed with AYA-onset CRC with no known history of familial CRC syndromes, 116 had data on mismatch repair status; 94 confirmed MSS CRC. AYA-onset CRC patients were commonly found with left-sided rather than right-sided tumors (77.7% vs 21.8%) and late stage of disease (72.7% in stage III-IV vs 24.7% in stage I-II). Compared with adult-onset CRC (195 patients), AYA-onset MSS CRC had more patients with female gender (p = 0.042), signet ring cell/mucinous histology (P = 0.039), and perineuralinvasion (P = 0.004). On univariate analysis, male gender and mucinous/signet ring cell histology had significantly worse OS (P = 0.003 and P = 0.016, respectively) and remained significant in multivariate analysis. There was no differences in terms of DFS or OS in both age groups.
Conclusions
Sporadic MSS AYA-onset CRC in Thai patients was associated with female gender and aggressive pathological characteristics. However, there was no difference in survival outcome between AYA-onset and adult-onset groups.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Siriraj Research Fund.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2667 - The impact of late-line treatment on overall survival (OS) from the initiation of first-line chemotherapy (CT) for patients (pts) with metastatic colorectal cancer (mCRC).
Presenter: Takeshi Kawakami
Session: Poster Display session 2
Resources:
Abstract
3139 - Efficacy and safety of FOLFIRI/Aflibercept (FA) in elderly population with mCRC after failure of oxaliplatin-based chemotherapy.
Presenter: Nieves Martinez Lago
Session: Poster Display session 2
Resources:
Abstract
3446 - Fluoropyrimidine-induced cardiotoxicity in colorectal cancer patients: preliminary data from the prospective observational CHECKPOINT trial (NCT02665312)
Presenter: Pasquale Lombardi
Session: Poster Display session 2
Resources:
Abstract
4455 - Impact of primary tumor side on 3-year survival outcomes of first-line (1L) FOLFOX-4 ± cetuximab in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 3 TAILOR trial
Presenter: Shukui Qin
Session: Poster Display session 2
Resources:
Abstract
4481 - Undetectable RAS mutant clones in plasma: possible implication for therapy and prognosis in the patient with RAS mutant metastatic colorectal cancer?
Presenter: Mohamed Bouchahda
Session: Poster Display session 2
Resources:
Abstract
5074 - Dihydropyrimidine dehydrogenase (DPD) determination prior the administration of medicines containing fluorouracil: a single Spanish hospital experience.
Presenter: Maria Dolores Mediano Rambla
Session: Poster Display session 2
Resources:
Abstract
5242 - Differences in survival between right and left-sided colorrectal cancer (CRC) in every stage, a CARESS-CCR Group Study.
Presenter: Julia Alcaide-Garcia
Session: Poster Display session 2
Resources:
Abstract
1123 - Quality of Life (QoL) in patients with aflibercept (AFL) and FOLFIRI for metastatic colorectal cancer (mCRC) – Interim analysis with focus on mutational status of the non-interventional study QoLiTrap (AIO-LQ-0113)
Presenter: Roger von Moos
Session: Poster Display session 2
Resources:
Abstract
1212 - The cost of adverse event management in patients with RAS wild-type metastatic colorectal cancer treated with first-line cetuximab and panitumumab: an Italian healthcare payer perspective
Presenter: Karl Patterson
Session: Poster Display session 2
Resources:
Abstract
1619 - Meta-analysis of KRAS Mutation as prognostic factor in patients (pts.) with resection of colorectal (CRC) liver metastases: Tumor burden and Sideness analysis.
Presenter: Maria Romina Luca
Session: Poster Display session 2
Resources:
Abstract